OncoMed Pharmaceuticals, Inc.OMED was a big mover last session, as the company saw its shares rise above 6% on the day. The upside came on the company's announcement that data related to three of its clinical-stage programs will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This continues the recent uptrend for the company as the stock is now up almost 47% in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision while the Zacks Consensus Estimate moved higher, suggesting that more solid trading could be ahead for OncoMed Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
OncoMed Pharmaceuticals carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked medical-biomedical/gene stock is Actelion Ltd. ALIOF , which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report